Maravai LifeSciences (MRVI)

• Market cap: $303M
• 1 day: -4.52%
• 5 days: -10.21%
• 1 month: -30.13%
• 3 months: -62.85%
• 6 months: -72.45%
• Year to date: -61.57%
• 1 year: -75.49%
• 5 years: -92.93%
• 10 years: -92.93%
• Sector: Healthcare
• Industry: Biotechnology

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

737% more call options, than puts

Call options by funds: $2.11M | Put options by funds: $252K

5% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 62

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

1.36% less ownership

Funds ownership: 104.57% [Q3] → 103.22% (-1.36%) [Q4]

16% less funds holding

Funds holding: 216 [Q3] → 181 (-35) [Q4]

34% less capital invested

Capital invested by funds: $1.23B [Q3] → $815M (-$415M) [Q4]

56% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 57

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2.50 18% upside
• Avg. target: $4.63 119% upside
• High target: $8 279% upside

4 analyst ratings

• positive: 1 25%
• neutral: 3 75%
• negative: 0 0%

Morgan Stanley Tejas Savant 21% 1-year accuracy 4 / 19 met price target	137% upside $5	Equal-Weight Maintained	25 Mar 2025
UBS Dan Brennan 29% 1-year accuracy 8 / 28 met price target	18% upside $2.50	Neutral Maintained	21 Mar 2025
B of A Securities Michael Ryskin 60% 1-year accuracy 3 / 5 met price target	279% upside $8	Buy Maintained	3 Mar 2025
Baird Catherine Schulte 0% 1-year accuracy 0 / 20 met price target	42% upside $3	Neutral Downgraded	26 Feb 2025